143 related articles for article (PubMed ID: 27222706)
1. Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms.
Yu C; Yang Q; Chen Y; Wang D; Levine R; Crispino J; Wen Q; Huang Z
Cell Biosci; 2016; 6():34. PubMed ID: 27222706
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
[TBL] [Abstract][Full Text] [Related]
3. Development of a Real-Time qPCR Assay for Detection of Common MPL Mutations in Myeloproliferative Neoplasms (MPNS).
Ullah N; Khan SN; Umair M; Khan AA; Liu X; Khattak AA; Yousafzai YM
Appl Biochem Biotechnol; 2022 Dec; 194(12):5907-5917. PubMed ID: 35838887
[TBL] [Abstract][Full Text] [Related]
4. MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.
Akpınar TS; Hançer VS; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2013 Mar; 30(1):8-12. PubMed ID: 24385746
[TBL] [Abstract][Full Text] [Related]
5. Assessment of intestinal status in MPL
Zhu S; Xu K; Li S; Yu X; Liu Y; Zhang Q; Zeng L; Xu K; Fu C
Int Immunopharmacol; 2023 Dec; 125(Pt A):111091. PubMed ID: 37883814
[TBL] [Abstract][Full Text] [Related]
6. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
7. Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.
Xie J; Chen X; Gao F; Hou R; Tian T; Zhang Y; Fan L; Hu J; Zhu G; Yang W; Wang H
Cancer Med; 2019 Sep; 8(11):5254-5263. PubMed ID: 31294534
[TBL] [Abstract][Full Text] [Related]
8. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
9. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
10. Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.
Morrell R; Langabeer SE; Smyth L; Perera M; Crotty G
Case Rep Hematol; 2013; 2013():729327. PubMed ID: 23970983
[TBL] [Abstract][Full Text] [Related]
11. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
12. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms.
Li Y; Gao H; Dong H; Wang W; Xu Z; Wang G; Liu Y; Wang H; Ju W; Qiao J; Xu K; Fu C; Zeng L
Biochem Pharmacol; 2022 May; 199():115013. PubMed ID: 35318038
[TBL] [Abstract][Full Text] [Related]
13. MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5.
Whetton AD; Azmi NC; Pearson S; Jaworska E; Zhang L; Blance R; Kendall AC; Nicolaou A; Taylor S; Williamson AJ; Pierce A
Oncotarget; 2016 Mar; 7(10):10739-55. PubMed ID: 26919114
[TBL] [Abstract][Full Text] [Related]
14. The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications.
Vainchenker W; Plo I; Marty C; Varghese LN; Constantinescu SN
Expert Rev Hematol; 2019 Jun; 12(6):437-448. PubMed ID: 31092065
[No Abstract] [Full Text] [Related]
15. An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report.
Hao L; Sen S; Sugumar D
Oncol Lett; 2015 Feb; 9(2):749-751. PubMed ID: 25621045
[TBL] [Abstract][Full Text] [Related]
16. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.
Michiels JJ; Tevet M; Trifa A; Niculescu-Mizil E; Lupu A; Vladareanu AM; Bumbea H; Ilea A; Dobrea C; Georgescu D; Patrinoiu O; Popescu M; Murat M; Dragan C; Mihai F; Zurac S; Angelescu S; Iova A; Popa A; Gogulescu R; Popov V
Maedica (Bucur); 2016 Mar; 11(1):5-25. PubMed ID: 28465746
[TBL] [Abstract][Full Text] [Related]
17. [AKT Is A Therapeutic Target in Myeloproliferative Neoplasms].
Yu J; Huang Z; Fan JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1105-1112. PubMed ID: 28823277
[TBL] [Abstract][Full Text] [Related]
18. JAK2
Zhan H; Ma Y; Lin CH; Kaushansky K
Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain.
Drachman JG; Kaushansky K
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2350-5. PubMed ID: 9122198
[TBL] [Abstract][Full Text] [Related]
20. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
